You are here

Home » Content

Hepatit C tedavisinde 2016 sağlık uygulama tebliğinin getirdiği yenilikler

Innovations of the 2016 communique of health application in the treatment of hepatitis C

Journal Name:

  • Online Türk Sağlık Bilimleri Dergisi

Publication Year:

  • 2016

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Success in hepatitis C treatment exceeds 90% with the oral direct-acting antivirals. Drugs within the scope of reimbursement vary from country to country. Two different combinations in our country (sofosbuvir-ledipasvir and ombitasvir-paritaprevir-ritonavir-dasabuvir) were included in the reimbursement from June 2016. However, regulations about the use of these combinations brought new conditions and limits on chronic hepatitis C treatment. In this review, hepatitis C treatment schemes and reimbursement terms in our country were revised with old and new rules.
Bookmark/Search this post with
Abstract (Original Language): 
Hepatit C tedavisindeki başarı direkt etkili oral antivirallerle %90’ları aşmaktadır. Geri ödeme kapsamındaki ilaçlar ülkeden ülkeye değişiklik göstermektedir. Ülkemizde iki farklı kombinasyon (sofosbuvir-ledipasvir ve ombitasvir-paritaprevir-ritonavir-dasabuvir) Haziran 2016’dan itibaren geri ödeme kapsamına alındı. Bununla birlikte bu kombinasyonlarla ilgili düzenlemeler kronik hepatit C tedavisinde yeni şartlar ve sınırlamalar getirdi. Bu derlemede ülkemizdeki hepatit C tedavi şemaları ve geri ödeme şartları eski ve yeni kurallarıyla gözden geçirilmiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-hepatit-c-tedavisinde-2016-saglik-uygulama-tebliginin-getirdigi-yenilikler.pdf
  • 2
23
29
  • Turkish

REFERENCES

References: 

1. http://www.resmigazete.gov.tr/default.aspx (Erişim tarihi:23.06.2016).
2. Tosun S . Viral hepatitlerin ülkemizdeki değişen epidemiyolojisi. ANKEM Derg 2013;27(Ek 2):128-134.
3. Chen SL. The Natural History of Hepatitis C Virus (HCV) Infection. International Journal
of Medical Sciences Int J Med Sci 2006;3(2):47-52.
4. Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Med Wkly. 2010 Jan 9;140(1-2):3-11.
5. American Association for the study of liver diseases (AASLD) and Infectious Diseases
Online Türk Sağlık Bilimleri Dergisi 2016, Cilt 1, Sayı 2, 23-29 Aziz ÖĞÜTLÜ
29
Society of America (IDSA). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C http://www.hcvguidelines.org (Erişim tarihi: 22.06.2016).
6. Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol. 2013 Dec 21;19(47):8963-73.
7. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98.
8. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594–603.
9. Holmes JA1, Thompson AJ1. Interferon-free combination therapies for the treatment of hepatitis C: current insights.Hepat Med. 2015 Nov 2;7:51-70.

Thank you for copying data from http://www.arastirmax.com